Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using ...
Constellation Pharmaceuticals is a clinical-sta...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the dev...
Verona Pharma plc is a clinical stage biopharma...
Opiant is a specialty pharmaceutical company developing medicines for addiction an...
Opiant is a specialty pharmaceutical company de...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Personalis, Inc. is a growing cancer genomics company transforming the development...
Personalis, Inc. is a growing cancer genomics c...
Join the National Investor Network and get the latest information with your interests in mind.